SAM
GYRE icon

Shamrock Asset Management’s Gyre Therapeutics GYRE Stock Holding History

Shamrock Asset Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1
Closed – – 270
2016
Q1 		$0 Hold
1
– – ﹤0.01% 265
2015
Q4 		$0 Hold
1
– – ﹤0.01% 260
2015
Q3 		$0 Hold
1
– – ﹤0.01% 265
2015
Q2 		$1K Hold
1
– – ﹤0.01% 261
2015
Q1 		$1K Hold
1
– – ﹤0.01% 278
2014
Q4 		$1K Hold
1
– – ﹤0.01% 245
2014
Q3 		$1K Hold
1
– – ﹤0.01% 243
2014
Q2 		$2K Buy
+1
New +$3.26K ﹤0.01% 264

Other funds holding GYRE

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Colorado Capital Management Boulder, Colorado $293M AUM 22.17% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Shamrock Asset Management's GYRE Position: Q2 2016 in Review

Shamrock Asset Management sold out of Gyre Therapeutics (GYRE) in Q2 2016, closing a stake of 1 share.

Shamrock Asset Management first reported a position in GYRE in Q2 2014 and held it in 8 quarters. The position peaked at $2K in Q2 2014. 31 funds tracked by Wall St. Rank hold GYRE as of Q2 2016.

  • Shamrock Asset Management reported no remaining Gyre Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Shamrock Asset Management sold 1 Gyre Therapeutics share in Q2 2016.
  • Shamrock Asset Management first reported a position in Gyre Therapeutics in Q2 2014 and held it in 8 quarters.
  • Shamrock Asset Management's Gyre Therapeutics position peaked at $2K in Q2 2014.
  • 31 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2016.

Based on Shamrock Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.